Genovis AB (publ.) (STO:GENO) just released its quarterly report and things are looking bullish. It was overall a positive result, with revenues beating expectations by 6.3% to hit kr37m. Genovis AB (publ.) also reported a statutory profit of kr0.06, which was an impressive 100% above what the analysts had forecast. This is an important time for investors, as they can track a company’s performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
Following the latest results, Genovis AB (publ.)’s two analysts are now forecasting revenues of kr187.5m in 2027. This would be a huge 20% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to surge 107% to kr0.51. Yet prior to the latest earnings, the analysts had been anticipated revenues of kr187.1m and earnings per share (EPS) of kr0.50 in 2027. So it’s pretty clear that, although the analysts have updated their estimates, there’s been no major change in expectations for the business following the latest results.
See our latest analysis for Genovis AB (publ.)
There were no changes to revenue or earnings estimates or the price target of kr34.00, suggesting that the company has met expectations in its recent result.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Genovis AB (publ.)’s past performance and to peers in the same industry. It’s clear from the latest estimates that Genovis AB (publ.)’s rate of growth is expected to accelerate meaningfully, with the forecast 16% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 5.6% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 10% per year. Factoring in the forecast acceleration in revenue, it’s pretty clear that Genovis AB (publ.) is expected to grow much faster than its industry.
The Bottom Line
The most important thing to take away is that there’s been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it’s tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At least one analyst has provided forecasts out to 2028, which can be seen for free on our platform here.
That said, it’s still necessary to consider the ever-present spectre of investment risk. We’ve identified 1 warning sign with Genovis AB (publ.) , and understanding this should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
